Abstract 11544: Rosuvastatin Dose-dependently Improves Flow-mediated Dilation, but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients
Background: Genetic analysis from patients participated in the randomized trials reported that the increased risk of type 2 diabetes noted with statins is at least partially explained by HMG-coenzyme A reductase inhibition. We investigated vascular and metabolic phenotypes of different dosages of rosuvastatin in hypercholesterolemic patients.
Methods: This was a randomized, single-blind, placebo-controlled, parallel study. Age, sex, and body mass index were matched among groups. Forty-eight patients were given placebo, and 47, 48, and 47 patients given rosuvastatin 5,10, and 20 mg, respectively daily during a 2 month treatment period.
Results: Placebo therapy did not significantly change insulin, adiponectin, glycated hemoglobin, and insulin sensitivity relative to baseline measurements. Rosuvastatin 5,10, and 20 mg dose-dependently and significantly improved flow-mediated dilation (34, 40, and 46%) after 2 months therapy when compared with baseline (P<0.001 by paired t-test) or when compared with placebo (P<0.001 by ANOVA). Rosuvastatin 5,10, and 20 mg dose-dependently and significantly increased insulin (median % changes; 16, 20, and 20%, respectively) and glycated hemoglobin levels (mean % changes; 2, 2, and 3%, respectively), and decreased adiponectin levels (mean % changes; 3, 9, and 14%, respectively) and insulin sensitivity (mean % changes; 2, 3, and 4%, respectively) after 2 months therapy when compared with either baseline (all P<0.05 by paired t-test). These effects with rosuvastatin 5,10, and 20 mg were significant when compared with placebo (P=0.006 for insulin, P=0.012 for glycated hemoglobin, P=0.007 for adiponectin, and P=0.002 for insulin sensitivity by ANOVA).
Conclusions: Despite beneficial reductions in LDL cholesterol and improvement of flow-mediated dilation, rosuvastatin treatment dose-dependently and significantly resulted in decreasing insulin sensitivity and increasing ambient glycemia by reducing adiponectin levels and increasing insulin levels in hypercholesterolemic patients.
Author Disclosures: K.K. Koh: None. S.H. Han: None. P.C. Oh: None.
- © 2016 by American Heart Association, Inc.